Ketek Labeling Gets Updated Warning, But Not Format, After Liver Toxicity
Executive Summary
Sanofi-Aventis is making a relatively modest labeling change to its antibiotic Ketek (telithromycin) following reports of hepatoxicity
You may also be interested in...
FDA Panel Supports Ketek as Second-Line for CAP; Suggests Black Box
Sanofi-Aventis' Ketek should not be the first-line treatment for community acquired pneumonia, members of an FDA advisory panel cautioned when they recommended continued marketing of the antibiotic for CAP
FDA Panel Supports Ketek as Second-Line for CAP; Suggests Black Box
Sanofi-Aventis' Ketek should not be the first-line treatment for community acquired pneumonia, members of an FDA advisory panel cautioned when they recommended continued marketing of the antibiotic for CAP
Two Strikes For Ketek: Cmtes. Want Bronchitis, Sinusitis Indications Rescinded
FDA's Anti-Infective Drug and Drug Safety and Risk Management Advisory Committees are recommending stripping Sanofi-Aventis' Ketek of its bronchitis and sinusitis indications